These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38219917)

  • 41. Romidepsin: in the treatment of T-cell lymphoma.
    Yang LP
    Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.
    Kelly-Sell MJ; Kim YH; Straus S; Benoit B; Harrison C; Sutherland K; Armstrong R; Weng WK; Showe LC; Wysocka M; Rook AH
    Am J Hematol; 2012 Apr; 87(4):354-60. PubMed ID: 22367792
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Romidepsin for the treatment of non-Hodgkin's lymphoma.
    Yazbeck VY; Grant S
    Expert Opin Investig Drugs; 2015; 24(7):965-79. PubMed ID: 25936363
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Romidepsin enhances the efficacy of cytarabine
    Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua GA; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS
    Haematologica; 2019 Jul; 104(7):e300-e303. PubMed ID: 30679330
    [No Abstract]   [Full Text] [Related]  

  • 45. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
    Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
    Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-cell lymphoma.
    Samimi S; Morrissey K; Anshelevich S; Evans K; Gardner J; Musiek A; Vittorio C; Rook A; Kim E
    J Am Acad Dermatol; 2013 Jan; 68(1):e5-6. PubMed ID: 23244387
    [No Abstract]   [Full Text] [Related]  

  • 47. The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.
    Horwitz SM
    Curr Hematol Malig Rep; 2011 Mar; 6(1):67-72. PubMed ID: 21080243
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
    Zhang W; Peyton M; Xie Y; Soh J; Minna JD; Gazdar AF; Frenkel EP
    J Thorac Oncol; 2009 Feb; 4(2):161-6. PubMed ID: 19179890
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Romidepsin for cutaneous T-cell lymphoma.
    Prince HM; Dickinson M
    Clin Cancer Res; 2012 Jul; 18(13):3509-15. PubMed ID: 22535155
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.
    Martinez-Escala ME; Kuzel TM; Kaplan JB; Petrich A; Nardone B; Rosen ST; Guitart J
    JAMA Oncol; 2016 Jun; 2(6):790-3. PubMed ID: 27054291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Romidepsin (Istodax
    Ro T; Nakayama N; Achiwa H; Ohtsu T
    Nihon Yakurigaku Zasshi; 2018; 151(3):122-129. PubMed ID: 29526921
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
    Fournier JF; Bhurruth-Alcor Y; Musicki B; Aubert J; Aurelly M; Bouix-Peter C; Bouquet K; Chantalat L; Delorme M; Drean B; Duvert G; Fleury-Bregeot N; Gauthier B; Grisendi K; Harris CS; Hennequin LF; Isabet T; Joly F; Lafitte G; Millois C; Morgentin R; Pascau J; Piwnica D; Rival Y; Soulet C; Thoreau É; Tomas L
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2985-2992. PubMed ID: 30122227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
    Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
    Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies.
    Makena MR; Nguyen TH; Koneru B; Hindle A; Chen WH; Verlekar DU; Kang MH; Reynolds CP
    Anticancer Drugs; 2021 Jan; 32(1):34-43. PubMed ID: 33079733
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma.
    Jain S; Jirau-Serrano X; Zullo KM; Scotto L; Palermo CF; Sastra SA; Olive KP; Cremers S; Thomas T; Wei Y; Zhang Y; Bhagat G; Amengual JE; Deng C; Karan C; Realubit R; Bates SE; O'Connor OA
    Clin Cancer Res; 2015 May; 21(9):2096-106. PubMed ID: 25677697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
    Rangwala S; Zhang C; Duvic M
    Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.
    Piekarz RL; Robey R; Sandor V; Bakke S; Wilson WH; Dahmoush L; Kingma DM; Turner ML; Altemus R; Bates SE
    Blood; 2001 Nov; 98(9):2865-8. PubMed ID: 11675364
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
    Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
    J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD.
    Brunvand MW; Carson J
    Hematol Oncol; 2018 Feb; 36(1):340-343. PubMed ID: 28560733
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma.
    Kim EJ; Kim YH; Rook AH; Lerner A; Duvic M; Reddy S; Robak T; Becker JC; Samtsov A; McCulloch W; Waksman J; Whittaker S
    Leuk Lymphoma; 2015; 56(10):2847-54. PubMed ID: 25791237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.